HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Summit Therapeutics (NASDAQ:SMMT) and maintained a price target of $16.
August 15, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Summit Therapeutics and maintained a price target of $16.
The reiteration of a Buy rating and a maintained price target of $16 by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100